Class II — Moderate Risk Severity Status: Ongoing Authority: FDA

CARVEDILOL

Recalling Firm / Manufacturer: Glenmark Pharmaceuticals Inc., USA (Mahwah, NJ, United States)
FDA Recall Number: D-0587-2025
View FDA Source
Source Authority Disclaimer: This drug recall notice is published by Questo using official enforcement reports issued by the U.S. Food & Drug Administration (FDA). It is provided for informational, academic, and clinical research purposes only. Patients should not discontinue prescribed treatments without consulting their physician or pharmacist.
Product & Identification Information
Brand, active ingredients, NDC codes, and manufacturer details
Brand / Trade Name
CARVEDILOL
Generic Name
CARVEDILOL
Active Substance(s)
Carvedilol
Administration Route
Oral
National Drug Code (NDC)
68462-162
Total Quantity Recalled
17, 496 bottles
Official Reason for Recall
Specific hazard or quality defect cited by the FDA

According to the official FDA enforcement report:

CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm

Full Product Description
Packaging specifications and labeling details

Carvedilol Tablets, USP, 12.5 mg, 500 Tablets per carton, Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd., Plot No. 2, Phase-2, Pharma Zone SEZ, Pithampur, Dist.-Dhar, Madhya Pradesh 454 775, India. Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 47430, NDC 68462-164-05

Enforcement & Regulatory Details
FDA classification, report dates, and initiation authority
Health Hazard Classification
Class II
Current Action Status
Ongoing
FDA Enforcement Report Date
August 20, 2025
Firm Initiation Date
August 06, 2025
FDA Classification Date
Aug 14, 2025
Initiation Type
Voluntary: Firm initiated
Affected Lots & Batch Numbers
Product codes, lot numbers, and expiration dates
Lot #: 17241257, 17241258, 17241279, Exp. Date 06/2026
Distribution Information
Geographic scope of affected shipments

Nationwide within the USA

Safety Guidance & Actions
Standard FDA protocol for patients and healthcare providers
Patient Advisory
Check your prescription bottle or packaging against the affected lot numbers listed above. If your medication matches a recalled lot, contact your pharmacist for replacement guidance.
Healthcare Provider Guidance
Audit pharmacy stock and return affected lots to the distributor per manufacturer instructions. Notify patients where clinically indicated.

Official Source Provenance

Verified regulatory citation from U.S. FDA OpenFDA

Primary Data Source: U.S. Food & Drug Administration (FDA) OpenFDA API
Recall Number: D-0587-2025
Questo Retrieval Date: July 31, 2026 14:36 1785508613UTCC
View Official FDA Source

System Notice

Confirm Action